{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:49:31Z","timestamp":1758707371084},"reference-count":34,"publisher":"Scientific Scholar","content-domain":{"domain":["ruralneuropractice.com"],"crossmark-restriction":true},"short-container-title":["JNRP"],"abstract":"<jats:sec id=\"st1\"><jats:title>Objectives:<\/jats:title><jats:p>The objectives of the study were to compare the clinico-radiological profile, optical coherence tomography (OCT) parameters and outcome in Myelin Oligodendrocyte Glycoprotein-IgG-associated disorders (MOGAD) and Neuromyelitis Optica Spectrum disorder subtypes.<\/jats:p><\/jats:sec><jats:sec id=\"st2\"><jats:title>Materials and Methods:<\/jats:title><jats:p>This prospective study involved collection of data regarding neurological assessment, neuroimaging, cerebrospinal fluid analysis, OCT parameters, treatment and outcome. Disease severity and disability were assessed using Expanded Disability Status Scale and modified Rankin scale. Patients were categorized into aquaporin-4 (AQP4+), MOGAD, and double negative (DN; both AQP4 and MOG negative).<\/jats:p><\/jats:sec><jats:sec id=\"st3\"><jats:title>Results:<\/jats:title><jats:p>Among 31 patients included, 42% were AQP4+, 32.2% were MOGAD, and 25.7% were DN. The median age at onset was comparable (AQP4+ vs. MOGAD vs. DN = 28 years vs. 24.4 years vs. 31.5years;<jats:italic>P<\/jats:italic>= 0.31). Females predominated in AQP4+ compared to MOGAD group (76.9% vs. 30%;<jats:italic>P<\/jats:italic>= 0.02). Majority of patients (73.5%) had a relapsing course with a median of two (range = 1\u20139) relapses. Ninety-nine demyelinating events occurred: Transverse myelitis (TM) in 60\/99 (60.6%), optic neuritis (ON) in 43\/99 (43.4%), area postrema (AP) syndrome in 20\/99 (20.1%), and optico-spinal syndrome in 10\/99 (10.1%). ON was common in MOGAD than AQP4+ patients (58.6% vs. 32.1%;<jats:italic>P<\/jats:italic>= 0.03). Spinal cord and brain lesions on magnetic resonance imaging (MRI) were seen in 90.3% and 54.8% patients, respectively. A significantly higher proportion of AQP4+ patients showed longitudinally extensive transverse myelitis as compared to MOGAD group (69.2 % vs. 20 %;<jats:italic>P<\/jats:italic>= 0.04), specifically involving dorsal cord (92.3% vs. 50%;<jats:italic>P<\/jats:italic>= 0.02). MRI brain lesions, especially involving AP, was frequent in DN than MOGAD (47.1% vs. 6.9%;<jats:italic>P<\/jats:italic>= 0.003) and AQP4+ (47.1% vs. 18.9%;<jats:italic>P<\/jats:italic>= 0.03) patients. AQP4+ group showed significant nasal RNFL thinning on OCT (<jats:italic>P<\/jats:italic>= 0.04). Although 6-month good functional outcome was better in MOGAD than DN and AQP4+ (80% vs. 71.4% vs. 41.7%) groups, they were comparable (<jats:italic>P<\/jats:italic>= 0.13).<\/jats:p><\/jats:sec><jats:sec id=\"st4\"><jats:title>Conclusion:<\/jats:title><jats:p>Nearly three-fourth of our patients showed a relapsing course, with TM being the most common clinical presentation. AQP4+ group showed female preponderance, frequent dorsal cord longitudinally extensive transverse myelitis, less frequent ON, and greater nasal RNFL thinning compared to MOGAD group. MRI brain lesions were more common in DN patients. All three groups exhibited good response to pulse corticosteroids and showed a comparable functional outcome at 6-month follow-up.<\/jats:p><\/jats:sec>","DOI":"10.25259\/jnrp_8_2022","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:18:46Z","timestamp":1677151126000},"page":"239-251","update-policy":"http:\/\/dx.doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study"],"prefix":"10.25259","volume":"14","author":[{"given":"Nikita","family":"Dhar","sequence":"first","affiliation":[{"name":"Department of Neurology, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mritunjai","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Neurology, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Neurology, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanuj","family":"Samanta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajeet Singh","family":"Bhadoria","sequence":"additional","affiliation":[{"name":"Department of Community and Family Medicine, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vivekanandhan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of Radiology, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Neurology, AIIMS, Rishikesh, Uttarakhand, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"10.25259\/JNRP_8_2022\/ref-1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/CON.0000000000000742","article-title":"Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Contin Lifelong Learn Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1177\/1352458514521503","article-title":"Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India","volume":"20","author":"Pandit","year":"2014","journal-title":"Mult Scler J"},{"key":"10.25259\/JNRP_8_2022\/ref-3","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","article-title":"Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies","volume":"73","author":"Ratchford","year":"2009","journal-title":"Neurology"},{"key":"10.25259\/JNRP_8_2022\/ref-5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/0972-2327.128559","article-title":"A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort","volume":"17","author":"Barhate","year":"2014","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/aian.aian_406_21","article-title":"A comparative analysis of clinical and imaging features of Aquaporin 4 (AQP4) antibody positive, Myelin oligodendrocyte glycoprotein (MOG) antibody positive and double seronegative subtypes of neuro myelitis optica spectrum disorder (NMOSD)","volume":"25","author":"Gupta","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4103\/aian.aian_860_21","article-title":"Comparison of clinical and radiological features of Aquaporin4 (AQP-4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and anti myelin oligodendrocyte glycoprotein (Anti-MOG) syndrome-our experience from Northwest India","volume":"25","author":"Jain","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4103\/0028-3886.294831","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated CNS demyelination: Clinical spectrum and comparison with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder","volume":"68","author":"Ojha","year":"2020","journal-title":"Neurol India"},{"key":"10.25259\/JNRP_8_2022\/ref-9","doi-asserted-by":"publisher","first-page":"577143","DOI":"10.1016\/j.jneuroim.2019.577143","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum-A north Indian tertiary care centre experience and review of literature","volume":"340","author":"Pedapati","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.25259\/JNRP_8_2022\/ref-10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/aian.AIAN_627_19","article-title":"Myelin oligodendrocyte glycoprotein (MOG)-IgG associated demyelinating disease: Our experience with this distinct syndrome","volume":"24","author":"Pujari","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.injms.2017.08.006","article-title":"Neuromyelitis optica spectrum disorders: An experience from tertiary care hospital of North-West India","volume":"8","author":"Sharma","year":"2017","journal-title":"Indian J Med Spec"},{"key":"10.25259\/JNRP_8_2022\/ref-12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/aian.AIAN_334_20","article-title":"Clinical features, gender differences, disease course, and outcome in neuromyelitis optica spectrum disorder","volume":"24","author":"Singh","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4103\/0972-2327.192389","article-title":"Serological markers associated with neuromyelitis optica spectrum disorders in South India","volume":"19","author":"Pandit","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.4103\/0028-3886.355118","article-title":"Neuromyelitis optica spectrum disorders in North Indian population: Experience from a tertiary care center","volume":"70","author":"Sachdeva","year":"2022","journal-title":"Neurol India"},{"key":"10.25259\/JNRP_8_2022\/ref-15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4103\/0976-3147.158755","article-title":"Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience","volume":"6","author":"Jagtap","year":"2015","journal-title":"J Neurosci Rural Pract"},{"key":"10.25259\/JNRP_8_2022\/ref-16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jneuroim.2021.577742","article-title":"Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature","volume":"361","author":"Nagireddy","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.25259\/JNRP_8_2022\/ref-17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.25259\/JNRP_8_2022\/ref-18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/2013.jamaophthalmol.354","article-title":"Visual acuity changes in patients with leber congenital amaurosis and mutations in CEP290","volume":"131","author":"McAnany","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.25259\/JNRP_8_2022\/ref-20","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","article-title":"Improving the assessment of outcomes in stroke: Use of a structured interview to assign grades on the modified Rankin Scale","volume":"33","author":"Wilson","year":"2002","journal-title":"Stroke"},{"key":"10.25259\/JNRP_8_2022\/ref-21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.25259\/JNRP_8_2022\/ref-22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737175.2016.1150178","article-title":"Therapeutic options in neuromyelitis optica spectrum disorders","volume":"16","author":"Kitley","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.25259\/JNRP_8_2022\/ref-23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/0972-2327.37815","article-title":"Neuromyelitis optica","volume":"10","author":"Jacob","year":"2007","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult Scler J"},{"key":"10.25259\/JNRP_8_2022\/ref-26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.msard.2019.01.032","article-title":"Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India","volume":"30","author":"Netravathi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.25259\/JNRP_8_2022\/ref-27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: A multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"10.25259\/JNRP_8_2022\/ref-28","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: Comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.25259\/JNRP_8_2022\/ref-29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00415-020-10300-z","article-title":"Myelin oligodendrocyte glycoprotein-antibody-associated disorder: A new inflammatory CNS demyelinating disorder","volume":"268","author":"Netravathi","year":"2021","journal-title":"J Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12883-014-0162-7","article-title":"Neuromyelitis optica spectrum disorders without and with autoimmune diseases","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Neurol"},{"key":"10.25259\/JNRP_8_2022\/ref-31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.25259\/JNRP_8_2022\/ref-32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ncn3.12528","article-title":"Role of optical coherence tomography in determining specific diagnostic pattern of retinal nerve fiber layer involvement in various central nervous system demyelinating diseases: An observational study","volume":"9","author":"Khandelwal","year":"2021","journal-title":"Neurol Clin Neurosci"},{"key":"10.25259\/JNRP_8_2022\/ref-33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/jcm10040609","article-title":"Optical coherence tomography angiography of peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder: A comparative study","volume":"10","author":"Rogaczewska","year":"2021","journal-title":"J Clin Med"},{"key":"10.25259\/JNRP_8_2022\/ref-34","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurosciences in Rural Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ruralneuropractice.com\/comparison-of-clinico-radiological-profile-optical-coherence-tomography-parameters-and-outcome-in-mogad-and-neuromyelitis-optica-spectrum-disorder-subtypes-a-prospective-observational-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ruralneuropractice.com\/comparison-of-clinico-radiological-profile-optical-coherence-tomography-parameters-and-outcome-in-mogad-and-neuromyelitis-optica-spectrum-disorder-subtypes-a-prospective-observational-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:53:21Z","timestamp":1728953601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ruralneuropractice.com\/comparison-of-clinico-radiological-profile-optical-coherence-tomography-parameters-and-outcome-in-mogad-and-neuromyelitis-optica-spectrum-disorder-subtypes-a-prospective-observational-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":34,"alternative-id":["10.25259\/JNRP_8_2022"],"URL":"https:\/\/doi.org\/10.25259\/jnrp_8_2022","relation":{},"ISSN":["0976-3155","0976-3147"],"issn-type":[{"type":"electronic","value":"0976-3155"},{"type":"print","value":"0976-3147"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"239"}}